Wells Fargo analyst Roger Read maintains HollyFrontier (NYSE:HFC) with a Equal-Weight and raises the price target from $31 to $35.
NorthStar Medical Radioisotopes, POINT Biopharma Announce Supply Agreement For Therapeutic Medical Radioisotope Actinium-225
NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and POINT Biopharma Global